Abstract:Enzymatic degradation of heparin by heparin lyases has not only largely facilitated heparin structural analysis and contamination detection, but also showed great potential to be a green and cost-effective way to produce low molecular weight heparin (LMWH). However, the commercial use of heparinase I (HepI), one of the most studied heparin lyases, has been largely hampered by its low productivity and extremely poor thermostability. Here we report the thermal inactivation mechanism and strategic thermal stabilization of maltose-binding protein (MBP)-HepI, a fusion HepI produced in E. coli with high yield, solubility and activity. Biochemical studies demonstrated that the thermal inactivation of MBP-HepI involves an unfolding step that is temperature-dependently reversible, followed by an irreversible dimerization step induced by intermolecular disulfide bonds. A good consistency between the kinetic modeling and experimental data of the inactivation was obtained within a wide range of temperature and enzyme concentration, confirming the adequacy of the proposed inactivation model. Based on the inactivation mechanism, a comprehensive strategy was proposed for the thermal stabilization of MBP-HepI, in which Ca(2+) and Tween 80 were used to inhibit unfolding while site mutation at Cys297 and DTT were employed to suppress dimerization. The engineered enzyme exhibits remarkably improved storage and operational thermostability, for example, 16-fold increase in half-life at its optimum temperature of 30 °C and 8-fold increase in remaining activity of 95% after 1-week storage at 4 °C, and therefore shows great potential as a commercial biocatalyst for heparin degradation in the pharmaceutical industry.

Production of Heparin Oligosaccharides by Fusion Protein of MBP–heparinase I and the Enzyme Thermostability

Biochemical analysis and kinetic modeling of the thermal inactivation of MBP-fused heparinase I: implications for a comprehensive thermostabilization strategy.

Combination of Site-Directed Mutagenesis and Calcium Ion Addition for Enhanced Production of Thermostable MBP-fused Heparinase I in Recombinant Escherichia Coli

Characterization of Maltose-Binding Protein-Fused Heparinases with Enhanced Thermostability by Application of Rigid and Flexible Linkers

Characteristics of low molecular weight heparin production by an ultrafiltration membrane bioreactor using maltose binding protein fused heparinase I

Construction of recombinant for over-production of soluble heparinase I by fusion to maltose-binding protein

Structure-based engineering of heparinase I with improved specific activity for degrading heparin

Controllable production of low molecular weight heparins by combinations of heparinase I/II/III.

Rational Design of a Tripartite Fusion Protein of Heparinase I Enables One-Step Affinity Purification and Real-Time Activity Detection.

Immobilized high-performance heparin lyase III for efficient preparation of low molecular weight heparin

Production of MBP–HepA Fusion Protein in Recombinant Escherichia Coli by Optimization of Culture Medium

Clonging and Expression of Heparinase III Gene from Flavobacterium heparinum and Characterization of the Recombinant Fusion Enzyme

Analysis of heparinase derived LMWH products using a MHC 2D LC system linked to Q-TOF MS

Optimization of Cultivation Conditions of Recombinant E.coli for Production of Soluble MBP-fused Heparinase I

High-Level Expression and Purification of Recombinant Heparinase Ⅰ in Escherichia Coli

Construction of MBP fusion heparinaseⅢ efficient expression system inE.coli

Preparation of Low Molecular Weight Heparin Using an Ultrasound-Assisted Fenton-system

Direct affinity immobilization of recombinant heparinase I fused to maltose binding protein on maltose-coated magnetic nanoparticles

Enzymatic synthesis of low molecular weight heparins from N-sulfo heparosan depolymerized by heparanase or heparin lyase

Construction Of Engineered E-Coli System For The Overproduction Of Soluble Heparinase I

Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin